Romano LGL, Miranda MJ, Vázquez LAA, Coronel CF, Guerra UP

Language: Spanish
References: 11
Page: 127-132
PDF size: 409.03 Kb.

ABSTRACT

Background: Hormone replacement therapy reestablishes the diminished hormonal level and reduces mild, moderate and severe effects of climacteric. Its treatment includes estrogens, progestagens and a mixture of both.
Objective: To evaluate the efficacy of intranasal and oral estrogens in the climacteric syndrome.
Material and methods: 60 patients were evaluated with climacteric syndrome; 30 received intranasal estrogens (group A) and 30 received oral estrogens (group B). Age range, 34-64 years. The symptoms were classified as vasomotor, collagen related symptoms and tropic changes. The patients were evaluated four times a week, and the symptoms were measured as mild, moderate and severe according with the Guía de evaluación de riesgo en la paciente climatérica.
Results: Group A (intranasal estrogens) showed faster clinical response in the first two weeks (63%), compared with group B (30%). No side effects were found in both groups.
Conclusions: Climacteric syndrome can be treated better and faster with intranasal estrogens than with oral estrogens, and without side effects.

REFERENCES

1. Norma Oficial Mexicana. NOM-035-SSA2-2002. Prevención y control de enfermedades en la perimenopausia y postmenopausia de la mujer. Disponible en http://www.salud.gob.mx/unidades/cdi/nom/035ssa202.html

2. Brunton L, Lazo J, Parker K. En: Las bases farmacológicas de la terapéutica de Goodman y Gilman. 8a ed. México: Mc Graw-Hill Interamericana, 1996;pp:1497-1527.

3. Basavilvazo RM, Díaz QA, Lemus RR. Terapia de reemplazo hormonal y cáncer de mama. Ginec Obstet Mex 2004;72:10-5.

4. Zayas JF, Elizondo AL, Gaxiola CM, Aragón ME. Efectos del tratamiento de reemplazo hormonal sobre el sistema cardiovascular, el hueso y la memoria en pacientes en etapa del climaterio. Ginec Obstet Mex 2004;72(1):16-22.

5. Watttanakumtornkul S, Pinto AB, William DB. Intranasal hormone remplacement therapy. Menopause 2003;10(1):88-98.

6. Devissaguet JP, Brion N, Lhote O, Deloffre P. Pulsed estrogen therapy: pharmacokinetics of intranasal 17-beta-estradiol (SD21400) in postmenopausal women and comparison with oral and transdermal formulations. Eur J Drug Metab Pharmacokinet 1999;24(3):265-71.

7. Plissier C, de Kervasdoue A, Chuong VT, Maugis EL, et al. Clinical evaluation, dose-finding and acceptability of AERODIOL, the pulsed estrogen therapy for treatment of climateric symptoms. Maturitas 2001;37(3):181-9.

8. Dooley M, Spencer CM, Ormrod D. Estradiol-intranasal: a review of its use in the management of menopause. Drugs 2001;61(15):2243-62.

9. Carranza LS. En: Atención integral al climaterio. 1ª ed. México: McGraw-Hill Interamericana, 1998;pp:249-87.

10. Zárate A, Basurto L. En: Endocrinología de la mujer: pubertad, etapa reproductiva y menopausia. ed. México: Editorial Prado, 2002;pp:150-5.

11. Studd J, Pornel B, Marton I, Bringer J, et al. Efficacy and aceptability of intranasal 17 beta-estradiol for menopausal symptoms: randomised dose-response study. Aerodiol Study Group. Lancet 1999;353(9164):1574-8.